SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovaserti ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) is a unique precision oncology company. IDYA leverages its synthetic lethality platform to exploit genetic vulnerabilities in cancer cells. The company mainly focuses on MTAP-deleted tumors and BRCA/HRD mutations. Its pipeline includes candidates such as Darovasertib, currently My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer sci ...

Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM study ASCO 2024 oral presentation of darovasertib in neoadjuvant UM; FDA Type C meeting for neoadjuvant UM in Q3'24 and targeting Phase 2 neoadjuvant UM data update in H2'24 Demonstrated preliminary proof-of-concept for IDE397 in MTAP urothelial and lung cancer; 1 PR awaiting confirmation has confirmed and 1 additional PR still awaiting confirmation, from the 2 uPRs ...

SOUTH SAN FRANCISCO, Calif., July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst About IDEAYA Biosciences Forward-Looking Statements Investor and Media Contact IDEAYA Biosciences Andres Ruiz ...

The public offering was made by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. ...

SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,228,572 shares of common stock and pre-funded warrants to purchase 285,715 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $35.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being ...

___________________ ___________________ SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $30.0 million of shares of its c ...

Management believes that theIDE397 study data demonstrates important clinical proof-of-concept in MTAPdeletion solid tumors to deliver meaningful responses and encourage preliminary durability of response with a convenient 30mg once-a-day tablet. The reported clinical efficacy and tolerability data are preliminary, drawn from an investigator-reviewed unlocked database as of the cutoff date of Jun 21, 2024. Per the data readout, the study achieved an overall response rate of 39%. Among the 18 evaluable patie ...

Group 1 - IDEAYA Biosciences, Inc. (IDYA) shares increased by 15.3% to close at $39.51, following a notable trading volume compared to typical sessions, contrasting with a 9.9% loss over the past four weeks [1][2] - The stock price surge was driven by positive clinical data from a phase II study of IDE397, which targets MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients, showing promising responses and durability of treatment [2] - The phase II clinical data involved 18 evaluable patients, including seven with urothelial cancer, four with adenocarcinoma NSCLC, and seven with squamous NSCLC, indicating significant clinical proof-of-concept for IDE397 [2] Group 2 - The consensus EPS estimate for IDEAYA has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Lexicon Pharmaceuticals (LXRX), experienced a 4.2% decline, reflecting a -4.6% return over the past month [7]

Key Takeaways IDEAYA Biosciences reported positive results from a Phase 2 trial of its experimental drug to treat certain bladder and small-cell lung cancers on Monday, and shares soared in intraday trading. The once-a-day tablet IDE397 helped patients with MTAP-deletion solid cancers. The company noted there are no Food and Drug Administration (FDA)-approved drugs for those who have MTAP-deletion solid tumors. Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announc ...